Background
Expanded knowledge of the pathogenesis behind diseases has led to the development of novel treatment strategies.
Functional and molecular imaging modalities are promising for non-invasive diagnosis and evaluation of treatment response at an earlier time point than morphological imaging.
The goals are to individualize diagnostic work-up and treatment, in order to optimize treatment outcome and minimize toxicity.
The group focuses on
- Clinical- and translational studies
- How to optimize image quality and to improve accuracy of disease detection
- In vivo tissue characterization and depiction of disease process
- Treatment response assessment
- Multimodality imaging
- Targeted radionuclide therapies
- Theranostic medicine
- Radiomics and artificial intelligence
Projects
- Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
- Characterization of vascular inflammation including vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
- Detection of inflammation treatment selection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
- Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
- Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT)
- Novel radionuclide therapies
- Molecular imaging and quantification of neurological diseases
- Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
- Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of tumor heterogeneity and disease patterns
Active external funded projects
- University of Oslo, Life Science, Convergence Environment: Fibro-PET (2022-27)
FIBRO-PET: Novel personalized management strategies for fibrosing diseases - UiO Life Science - Oslo University Hospital strategic research area (2022-27) (Co-PI)
FIBRO-MAN: Personalized management strategies for fibrosing diseases, integration of novel imaging techniques into clinical management in fibrosing diseases - RADFORSK, The Norwegian Radium Hospital Research Foundation strategic research area (2023-2028) (Co-PI)
TARACAN: Targeted Radionuclide Therapy for disseminated cancer - South-Eastern Norway Regional Health Authority/Norwegian Cancer Society (2020-2024)
Theranostic radiopharmaceuticals for metastatic cancer - South-Eastern Norway Regional Health Authority (2019-2024)
A novel PET-based prediction platform for myeloma patients - South-Eastern Norway Regional Health Authority and CarciNor (2018-24)
Clinical usefulness of advanced image analysis of 18F-FDG PET/CT for in vivo characterisation of neuroendocrine carcinomas - Civitan, The Alzheimer Research Fund (2018-2023)
Amyloid imaging by 18F-Flutemetamol PET/CT and MRI – clinical value and quantitative reference levels
Major international collaborations
- University of Pennsylvania and Perelman School of Medicine, Philadelphia, PA, USA
- Odense University Hospital and University of Southern Denmark, Denmark
- Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- Division of Cancer Sciences, The University of Manchester, The Christie NHS Foundation Trust, Manchester, UK
- Thomas Jefferson University, Philadelphia, PA, USA
- Indiana University School of Medicine, Indianapolis, IN, USA
- National Institutes of Health (NIH), Bethesda, MD, USA
Industry partners
- The Norwegian Cyclotron
- Center OncoInvent
- Sciencons AS
- Nucligen AS
- ArtBio
- Nordic Nanovector
- Institute for Energy Technology
- Blue Earth Diagnostics
- ARXX
- iSOFIE
- Siemens
- GE Health
